Across TCGA pan-cancer cohorts, RNU6ATAC25P RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of RNU6ATAC25P’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where RNU6ATAC25P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RNU6ATAC25P is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.

BRCA and THCA are the cancer types where RNU6ATAC25P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RNU6ATAC25P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	Female	II,III,IV	+0.076	.003	6	view →
THCA	All	All	−0.055	.026	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: RNU6ATAC25P RNA expression & survival · all RNU6ATAC25P data types